CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展

李丽; 赵长久; 田国梅; 李丽; 赵长久; 田国梅

doi:10.3760/cma.j.issn.1673-4114.2014.03.012

[1]

Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in prostate cancer[J]. Endocr Relat Cancer, 2009, 16(3): 663-673. doi: 10.1677/ERC-09-0109

[2]

Chu H, Zhou H, Liu Y, et al. Functional expression of CXC chemokine receptor-4 mediates the secretion of matrix metalloproteinases from mouse hepatocarcinoma cell lines with different lymphatic metastasis ability[J]. Int J Biochem Cell Biol, 2007, 39(1): 197-205. doi: 10.1016/j.biocel.2006.07.008

[3]

Duda DG, Kozin SV, Kirkpatrick ND, et al. CXCL12(SDF1α)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?[J]. Clin Cancer Res, 2011, 17(8): 2074-2080. doi: 10.1158/1078-0432.CCR-10-2636

[4]

Sun X, Cheng G, Hao M, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression[J]. Cancer Metastasis Rev, 2010, 29(4): 709-722. doi: 10.1007/s10555-010-9256-x

[5]

Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor[J]. Science, 1996, 272(5263): 827-877. doi: 10.1126/science.272.5263.827

[6]

Wu B, Chien EY, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists[J]. Science, 2010, 330(6007): 1066-1071. doi: 10.1126/science.1194396

[7]

Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide[J]. Eur J Cancer, 2013, 49(1): 219-230.

[8]

Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment[J]. Blood, 2006, 107(5): 1761-1767. doi: 10.1182/blood-2005-08-3182

[9]

Ratajczak MZ, Zuba-Surma E, Kucia M, et al. The plieotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis[J]. Leukemia, 2006, 20(11): 1915-1924. doi: 10.1038/sj.leu.2404357

[10]

Cojoc M, Peitzsch C, Trautmann F, et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis[J]. Onco Targets Ther, 2013, 6: 1347-1361.

[11]

Gerits N, Kostenko S, Shiryaev A, et al. Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility[J]. Cell Signal, 2008, 20(9): 1592-1607. doi: 10.1016/j.cellsig.2008.02.022

[12]

Wojcechowskyj JA, Lee JY, Seeholzer SH, et al. Quantitative phosphoproteomics of CXCL12 (SDF-1) signaling[J/OL]. PLoS One, 2011, 6(9): e24918[2013-08-28]. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0024918.

[13]

Princen K, Hatse S, Vermeire K, et al. Evaluation of SDF-1/CXCR4-induced Ca²⁺ signaling by fluorometric imaging plate reader(FLIPR) and flow cytometry[J]. Cytometry A, 2003, 51(1): 35-45.

[14]

New DC, Wong YH. Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression[J]. J Mol Signal, 2007, 2: 2. doi: 10.1186/1750-2187-2-2

[15]

Goel HL, Li J, Kogan S, et al. Integrins in prostate cancer progression[J]. Endocr Relat Cancer, 2008, 15(3): 657-664. doi: 10.1677/ERC-08-0019

[16]

Romain B, Hachet-Haas M, Rohr S, et al. Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer[J]. Mol Cancer, 2014, 13(1): 58.

[17]

Park BH, Kook S, Lee S, et al. An isoform of C/EBPβ, LIP, regulates expression of the chemokine receptor CXCR4 and modulates breast cancer cell migration[J]. J Biol Chem, 2013, 288(40): 28656-28667. doi: 10.1074/jbc.M113.509505

[18]

McIver SC, Loveland KL, Roman SD, et al. The chemokine CXCL12 and its receptor CXCR4 are implicated in human seminoma metastasis[J]. Andrology, 2013, 1(3): 517-529. doi: 10.1111/j.2047-2927.2013.00081.x

[19]

尹东, 张佐, 高素, 等.趋化因子受体CXCR4及其配体CXCL12在口腔鳞状细胞增殖和迁移中的作用[J].华西口腔医学杂志, 2013, 31(1): 8-12.

[20]

Mo W, Chen J, Patel A, et al. CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors[J]. Cell, 2013, 152(5): 1077-1090. doi: 10.1016/j.cell.2013.01.053

[21]

Cavallaro S. CXCR4/CXCL12 in Non-Small-Cell Lung Cancer Metastasis to the Brain[J]. Int J Mol Sci, 2013, 14(1): 1713-1727. doi: 10.3390/ijms14011713

[22]

Liberman J, Sartelet H, Flahaut M, et al. Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma[J/OL]. PloS one, 2012, 7(8): e43665[2013-08-28]. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0043665.

[23]

Cabioglu N, Sahin AA, Morandi P, et al. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications[J]. Ann Oncol, 2009, 20(6): 1013-1019. doi: 10.1093/annonc/mdn740

[24]

Mimeault M, Batra SK. New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence[J]. Histol Histopathol, 2010, 25(8): 1057-1073.

[25]

Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis[J]. Nature, 2001, 410(6824): 50-56. doi: 10.1038/35065016

[26]

Woodard LE, Nimmagadda S. CXCR4-based imaging agents[J]. J Nucl Med, 2011, 52(11): 1665-1669. doi: 10.2967/jnumed.111.097733

[27]

Yu S, Wang X, Liu G, et al. High Level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome[J]. Acta Med Okayama, 2013, 67(6): 369-375.

[28]

Gillies K, Wertman J, Charette N, et al. Anterograde trafficking of CXCR4 and CCR2 receptors in a prostate cancer cell line[J]. Cell Physiol Biochem, 2013, 32(1): 74-85.

[29]

Kryczek I, Wei S, Keller E, et al. Stroma-derived factor(SDF-1/ CXCL12) and human tumor pathogenesis[J]. Am J Physiol Cell Physiol, 2007, 292(3): 987-995. doi: 10.1152/ajpcell.00406.2006

[30]

Teicher BA, Fricker SP. CXCL12(SDF-1)/CXCR4 pathway in cancer[J]. Clin Cancer Res, 2010, 16(11): 2927-2931. doi: 10.1158/1078-0432.CCR-09-2329

[31]

Su L, Zhang J, Xu H, et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells[J]. Clin Cancer Res, 2005, 11(23): 8273-8280. doi: 10.1158/1078-0432.CCR-05-0537

[32]

Shim H, Oishi S, Fujii N. Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors[J]. Semin Cancer Biol, 2009, 19(2): 123-134.

[33]

Cheng M, Qin G. Progenitor cell mobilization and recruitment: SDF-1, CXCR4, α4-integrin, and c-kit[J]. Prog Mol Biol Transl Sci, 2012, 111: 243-264. doi: 10.1016/B978-0-12-398459-3.00011-3

[34]

牛作兴, 费立明, 王长亮, 等. CXCL12-CXCR4生物学轴在胰腺癌中的表达及其与血管生成的相关性[J].中华肿瘤杂志, 2009, 31(4): 286-287.

[35]

Hassan S, Buchanan M, Jahan K, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model[J]. Int J Cancer, 2011, 129(1): 225-232.

[36]

刘静, 郭华雄.趋化因子CXCL12/CXCR4生物轴在肿瘤中的研究进展[J].临床与实验病理学杂志, 2010, 26(4): 477-480. doi: 10.3969/j.issn.1001-7399.2010.04.023

[37]

Ramsey DM, McAlpine SR. Halting metastasis through CXCR4 inhibition[J]. Bioorq Med Chem, 2013, 23(1): 20-25.

[38]

Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals[J]. Cancer Cell, 2009, 16(1): 67-78.

[39]

Gassmann P, Haier J, Schlüter K, et al. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo[J]. Neoplasia, 2009, 11(7): 651-661. doi: 10.1593/neo.09272

[40]

Arigami T, Natsugoe S, Uenosono Y, et al. CCR7 and CXCR4 expression predicts lymph node status including micrometastasis in gastric cancer[J]. Int J Oncol, 2009, 35(1): 19-24.

[41]

Guo J, Lou W, Ji Y, et al. Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma[J]. Oncol Lett, 2013, 5(5): 1572-1578. doi: 10.3892/ol.2013.1261

[42]

杨文博, 孔佩艳.以SDF-1/CXCR4为靶点治疗疾病的研究进展[J].医学综述, 2010, 16(21): 3230-3232. doi: 10.3969/j.issn.1006-2084.2010.21.010

[43]

Takaoka K, Hidaka S, Hashitani S, et al. Effect of a nitric oxide synthase inhibitor and a CXC chemokine receptor-4 antagonist on tumor growth and metastasis in a xenotransplanted mouse model of adenoid cystic carcinoma of the oral floor[J]. Int J Oncol, 2013, 43(3): 737-745.

[44]

Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia(AML) following mobilization by the CXCR4 antagonist AMD3100[J]. Blood, 2009, 113(24): 6206-6214. doi: 10.1182/blood-2008-06-162123

[45]

Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers[J]. Leukemia, 2009, 23(1): 43-52. doi: 10.1038/leu.2008.299

[46]

Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice[J]. J Clin Invest, 2010, 120(3): 694-705. doi: 10.1172/JCI40283

[47]

师佳佳, 贾晓辉, 李晓红, 等.雷帕毒素对骨髓瘤细胞RPMI8226增殖、凋亡及趋化因子受体CXCR4表达的影响[J].中国实验血液学杂志, 2009, 17(2): 385-389.

[48]

DiPersio JF, Micallef IN, Stiff PJ, et al. Phase Ⅲ prospective randomized double-blind placebo-controlled trial for plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma[J]. J Clin Oncol, 2009, 27(28): 4767-4773. doi: 10.1200/JCO.2008.20.7209

[49]

Wang L, Huang T, Chen W, et al. Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells[J]. Oncol Rep, 2012, 28(6): 2043-2048.

[50]

Chen HY, Wang JM, Wang HY, et al. Effect of short hairpin RNA-induced CXCR4 silence on ovarian cancer cell[J]. Biomed Pharmacother, 2012, 66(7): 549-553. doi: 10.1016/j.biopha.2012.04.007

[51]

De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor(AMD3100, MozobilTM) and potential of other CXCR4 antagonists as stem cell mobilizers[J]. Pharmacol Ther, 2010, 128(3): 509-518. doi: 10.1016/j.pharmthera.2010.08.009

[52]

Jacobson O, Weiss ID, Szajek L, et al. ⁶⁴Cu-AMD3100-a novel imaging agent for targeting chemokine receptor CXCR4[J]. Bioorg Med Chem, 2009, 17(4): 1486-1493. doi: 10.1016/j.bmc.2009.01.014

[53]

Nimmagadda S, Pullambhatla M, Stone K, et al. Molecular imaging of CXCR4 receptor expression in human cancer xengografts with[⁶⁴Cu]AMD3100 positron emission tomography[J]. Cancer Res, 2010, 70(10): 3935-3944. doi: 10.1158/0008-5472.CAN-09-4396

[54]

Weiss ID, Jacobson O, Kiesewetter DO, et al. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of ⁶⁴Cu-AMD3100[J]. Mol Imaging Biol, 2012, 14(1): 106-114.

[55]

De Silva RA, Peyre K, Pullambhatla M, et al. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam ⁶⁴Cu-AMD3465[J]. J Nucl Med, 2011, 52(6): 986-993.

[56]

Nimmagadda S, Pullambhatla M, Pomper MG. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT[J]. J Nucl Med, 2009, 50(7): 1124-1130. doi: 10.2967/jnumed.108.061325

[57]

Tamamura H, Tsutsumi H, Fujii N. The chemokine receptor CXCR4 as a therapeutic target for several diseases[J]. Mini Rev Med Chem, 2006, 6(9): 989-995. doi: 10.2174/138955706778195135

[58]

Hanaoka H, Mukai T, Tamamura H, et al. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors[J]. Nucl Med Biol, 2006, 33(4): 489-494.

[59]

Jacobson O, Weiss ID, Kiesewetter DO, et al. PET of tumor CXCR4 expression with 4-¹⁸F-T140[J]. J Nucl Med, 2010, 51(11): 1796-1804. doi: 10.2967/jnumed.110.079418

[60]

George GP, Stevens E, Aberg O, et al. Preclinical evaluation of a CXCR4-specific ⁶⁸Ga-labelled TN14003 derivative for cancer PET imaging[J]. Bioorg Med Chem, 2014, 22(2): 796-803.

[61]

Misra P, Lebeche D, Ly H, et al. Quantitation of CXCR4 expression in myocardial infarction using ^99mTc-labeled SDF-1α[J]. J Nucl Med, 2008, 49(6): 963-969.

[62]

Meincke M, Tiwari S, Hattermann K, et al. Near-infrared molecular imaging of tumors via chemokine receptors CXCR4 and CXCR7[J]. Clin Exp Metastasis, 2011, 28(8): 713-720. doi: 10.1007/s10585-011-9403-y

[63]

Demmer O, Gourni E, Schumacher U, et al. PET imaging of CXCR4 receptors in cancer by a new optimized ligand[J]. Chem Med Chem, 2011, 6(10): 1789-1791. doi: 10.1002/cmdc.201100320

[64]

Zhang XX, Sun Z, Guo J, et al. Comparison of ¹⁸F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression[J]. Mol Imaging Biol, 2013, 15(6): 758-767. doi: 10.1007/s11307-013-0640-0

[65]

Hartimath SV, Domanska UM, Walenkamp AM, et al. [^99mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imaging[J]. Nucl Med Biol, 2013, 40(4): 507-517.